Collaboration to develop engineered bacteriophage therapeutics targeting bacterial pathogens responsible for serious eye infections
Locus Biosciences, a clinical-stage biotechnology company developing precision engineered bacteriophage treatments for a diverse set of bacterial diseases, announced a research collaboration agreement with Viatris Inc., a global healthcare company, to develop novel engineered bacteriophage products targeting ophthalmic bacterial infections.
Health Technology Insights: Omada Health Welcomes Thomas Tsang, as Chief Medical Officer
Locus and Viatris will collaborate to develop precision antibacterial therapeutics for serious eye infections
Under the terms of the agreement, Locus and Viatris will collaborate to develop precision antibacterial therapeutics for serious eye infections, an area of high unmet medical need due to the rise in antibiotic-resistant infections worldwide.
Locus’s proprietary development platform integrates predictive artificial intelligence (AI), high-throughput robotics, and synthetic biology to create bacteriophage cocktails that selectively eliminate pathogenic bacteria while sparing beneficial species.
Health Technology Insights: DIAGNOS Welcomes Dr. Pierre-Luc Charlebois to its Advisory Board
“This partnership with Viatris marks a significant milestone for Locus as we bring our world-leading bacteriophage therapy platform to ophthalmology,” said Paul Garofolo, Co-founder and CEO of Locus Biosciences. “Targeted therapies are urgently needed to address the growing burden of antimicrobial resistance in eye infections. We’re proud to work with Viatris to accelerate the development of new precision medicines for patients in need.”
This collaboration underscores the growing global recognition of phage therapy as a promising alternative or complement to traditional antibiotics—especially as antimicrobial resistance continues to rise amid decades of chronic under-investment in novel antibacterial treatment approaches.
Health Technology Insights: Philips Launches First CT-Cath Lab Sync for PCI Guidance
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
